Biotech stocks could sway toward the upside with the appointment of a new director at the Federal Drug Administration's Center for Drug Evaluation and Research. Dr. Richard Pazdur will take the reigns, bringing 26 years of related industry experience. The move was cheered by Wall Street analysts who view the appointment as a positive given Dr. Pazdur's experience in the industry as opposed to bringing in an outsider. The latter would typically bring uncertainty to a sector that President Trump was looking t ...